Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 8/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 6/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385091 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL14829529 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL12219205 | 0.90 | ADORA1 (0.81) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL12194756 | 0.90 | ADORA1 (0.81) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL9413315 | 0.90 | ADORA1 (0.81) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL2509912 | 0.90 | ADORA1 (0.81) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL31060441 | 0.89 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL2509742 | 0.89 | ADORA1 (0.80) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL6382804 | 0.86 | ADORA3 (1.00) | ADORA1ADORA3ADORA2AADORA2BALOX15 | |
| SCHEMBL22206514 | 0.85 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | UNIV ROCHESTER (US) | 2020-09-03 | — | — | US | claimed |
| EP-2704793-B1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV RAMOT (IL) | 2019-07-17 | — | — | EP | claimed |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | claimed |
| WO-2016183217-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY (US) | 2016-11-17 | — | — | WO | claimed |
| US-9192670-B2 | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-24 | — | — | US | claimed |
| EP-2704793-A1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Ramot at Tel Aviv University, Ltd. (IL) | 2014-03-12 | — | — | EP | claimed |
| WO-2012150600-A2 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-11-08 | — | — | WO | claimed |
| US-20250295604-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2025-09-25 | — | — | US | disclosed |
| EP-3399984-B1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230002389-A1 | ADENINE ANALOGS, PRODRUGS, DERIVATIVES, COMPOSITIONS AND USES THEREOF | PADIA JANAK KHIMCHAND (US) | 2023-01-05 | — | — | US | disclosed |
| US-20210371449-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2021-12-02 | — | — | US | disclosed |
| US-9192670-B2 | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-24 | — | — | US | disclosed |
| US-20140074181-A1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Ramot at Tel-Aviv Univerity Ltd. (IL) | 2014-03-13 | — | — | US | disclosed |
| EP-2704793-A1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Ramot at Tel Aviv University, Ltd. (IL) | 2014-03-12 | — | — | EP | disclosed |
| US-20130005676-A1 | ENHANCING THE THERAPEUTIC EFFECT OF ACUPUNCTURE WITH ADENOSINE | UNIVERSITY OF ROCHESTER (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2012150600-A2 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-11-08 | — | — | WO | disclosed |
| EP-2504347-A1 | ENHANCING THE THERAPEUTIC EFFECT OF ACUPUNCTURE WITH ADENOSINE | University Of Rochester (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066412-A1 | ENHANCING THE THERAPEUTIC EFFECT OF ACUPUNCTURE WITH ADENOSINE | UNIVERSITY OF ROCHESTER (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002389-A1 | ADENINE ANALOGS, PRODRUGS, DERIVATIVES, COMPOSITIONS AND USES THEREOF | APRT, HPRT1, NUDT1 | ADORA1 27/4885ADORA3 16/4885ADORA2A 13/4885 |
| US-20250295604-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA1 39/4885ADORA3 32/4885ADORA2A 10/4885 |
| US-20210371449-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | ADORA1 39/4885ADORA3 35/4885ADORA2A 19/4885 |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA1 39/4885ADORA3 32/4885ADORA2A 10/4885 |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | ADORA1 40/4885ADORA3 37/4885ADORA2A 19/4885 |
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | P2RX3, P2RX1, P2RX2 | ADORA1 4/4885ADORA3 13/4885ADORA2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.